Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNYNF) Inventory (2016 - 2025)

Historic Inventory for Sanofi (SNYNF) over the last 17 years, with Q4 2025 value amounting to $11.9 billion.

  • Sanofi's Inventory rose 1798.68% to $11.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.9 billion, marking a year-over-year increase of 1798.68%. This contributed to the annual value of $11.5 billion for FY2025, which is 1308.18% up from last year.
  • Per Sanofi's latest filing, its Inventory stood at $11.9 billion for Q4 2025, which was up 1798.68% from $10.9 billion recorded in Q2 2025.
  • In the past 5 years, Sanofi's Inventory registered a high of $11.9 billion during Q4 2025, and its lowest value of $9.1 billion during Q4 2022.
  • Its 5-year average for Inventory is $10.6 billion, with a median of $10.6 billion in 2023.
  • As far as peak fluctuations go, Sanofi's Inventory crashed by 1038.94% in 2022, and later soared by 1798.68% in 2025.
  • Over the past 5 years, Sanofi's Inventory (Quarter) stood at $10.0 billion in 2021, then dropped by 8.31% to $9.1 billion in 2022, then increased by 13.77% to $10.4 billion in 2023, then dropped by 3.1% to $10.1 billion in 2024, then rose by 17.99% to $11.9 billion in 2025.
  • Its Inventory stands at $11.9 billion for Q4 2025, versus $10.9 billion for Q2 2025 and $10.1 billion for Q4 2024.